- Helps to stabilize or increase the haemoglobin levels in most patients during the maintenance therapy.
- Results in a low need for blood transfusion during treatment and a low rate of breakthrough haemolysis.
- Improves the patient’s quality of life and reduces fatigue.
Eculizumab is indicated for the treatment of patients with:
•Paroxysmal nocturnal haemoglobinuria (PNH).
•Atypical haemolytic uremic syndrome (aHUS)
Eculizumab is supplied as a concentrate for solution for infusion as a 300 mg vial.